TABLE 3

Descriptive characteristics and unadjusted outcomes of patients with COPD for each measure of the standard set

6MWTCCQGPE-DVHHDMRC
Female patients1344 (51.1%)1786 (52.1%)636 (50.6%)223 (51.3%)1237 (52.7%)
Age, years67.8 (9.2)68.1 (9.4)68.2 (9.4)68.0 (9.2)68.2 (9.3)
Treatment episodes with baseline scores26283427N.A.4352348
Treatment episodes with end scores1822240812562181385
Range of scores on each measure6–780 m0–6 points1–7 points131–542 Nm1–5 points
Baseline scores+370.8 m
(126.3 m)
2.4 points
(0.9)
N.A.284.2 Nm
(96.4 Nm)
3.0 points
(1.1)
End scores373.5 m
(130.3 m)
2.2 points
(0.9)
3.5 points
(1.1)
298.4 Nm
(95.5)
3.0 points
(1.1)
Change (Tend–T0)2.7 (86.8)−0.1 (0.8)N.A.#8.4 (50.9)0.2 (1.3)
MCID improvement533 (28.7%)§818 (34.0%)ƒN.A.#99 (45.4%)##N.A.
MCID stabilisation807 (44.3%)§1052 (43.7%)ƒN.A.#43 (19.9%)##N.A.
MCID deterioration490 (26.9%)§537 (22.3%)ƒN.A.#76 (34.7%)##N.A.
Physical therapists who provided data145 (63.3%)202 (88.2%)117 (51.0%)46 (20.0%)168 (46.7%)
Practices that provided data86 (62.8%)126 (92.0%)72 (52.6%)28 (20.4%)107 (78.1%)
Practices that provided ≥10 cases44 (19.2%)61 (26.6%)35 (15.3%)10 (4.4%)43 (18.8%)
Patients included in the multilevel analysis1679 (36.0%)2201 (47.3%)1110 (23.8%)160 (3.4%)1226 (26.4%)

Data are presented as means (sd) or numbers and percentages of patients with baseline measures.

6MWT: 6-min walk test; CCQ: Clinical COPD Questionnaire; GPE-DV: Global Perceived Effect – Dutch Version; HHD: hand-held dynamometer; MRC: Medical Research Council Dyspnoea Scale; MCID: minimal clinically important difference; N.A: not applicable. #GPE-DV was only analysed at the end of the treatment. The MCID for the MRC is yet to be established [24]. +For treatment episodes with end scores. §For the multilevel analysis of the 6MWT, we used an MCID of ± ≥30 m [33]. ƒFor the multilevel analysis of the CCQ, we used an MCID of ± ≥0.4 points [34]. ##For the multilevel analysis of the HHD, we used an MCID of ± ≥7.5 Nm [35].